Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 J&J Bids $2.3 Billion for Crucell | Contract Pharma

What are you searching for?

Sign in
Breaking News

J&J Bids $2.3 Billion for Crucell

Johnson & Johnson has made a bid to acquire all outstanding shares of Crucell N.V. for $2.3 billion in cash.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Johnson & Johnson has made a bid to acquire all outstanding shares of Crucell N.V. for $2.3 billion in cash. J&J currently holds approximately 17.9% of Crucell’s total issued shares.

The two companies entered negotiations in September 2010. Crucell’s management board and supervisory board unanimously supported the offer. The acceptance period for the offer begins on December 9th and, unless extended, ends on February 16, 2011.

J&J expects to maintain Crucell’s existing facilities, senior management, and Crucell’s current employment levels. J&J also plans to keep Crucell as the center for vaccines within J&J’s pharmaceuticals group and to maintain Crucell’s headquarters in Leiden.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters